R&D

SMART DRUG DELIVERY PLATFORM
BASED ON CELL-DERIVED VESICLES

R&D

Anticancer Drug/Personalized Anticancer Drug/Osteoarthritis/COPD/Neurodegenerative Diseases

Neurodegenerative
diseases

  • 01
    Alzheimer's
    Disease
    Alzheimer's disease was first identified by German neuropathologist Dr. Alois Alzheimer in 1906. As the most common form of dementia, Alzheimer's disease accounts for 60-70% of total dementia cases.
    In the absence of a cure, Alzheimer’s disease represents an area of the highest unmet medical need.
    There is a crucial need to develop therapeutics to treat Alzheimer's disease as it would improve the quality of life for the elderly as well as alleviate exorbitant socioeconomic burdens caused by a rapid increase in aging populations.
  • 02
    Therapeutics
    Development
    Nanosized stem cell-derived vesicles are a strong candidate for neurodegenerative disease therapeutics because of their capability to penetrate the blood-brain barrier (BBB).
    The neuroprotective effects of stem cell-derived vesicles were observed in a dose-dependent manner in in vitro model of Alzheimer's disease.
    The effects of stem cell-derived vesicle treatment in neuroprotection and neurogenesis will be investigated using animal models of Alzheimer's disease. This study is conducted in collaboration.